Axonics Modulation Technologies Inc Net Assets
Axonics Modulation Technologies Inc net assets. Based on the latest financial reports, Axonics Modulation Technologies Inc (AXNX) has net assets worth $664.49 Million USD as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($774.17 Million) and total liabilities ($109.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See AXNX equity financing ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $664.49 Million |
| % of Total Assets | 85.83% |
| Annual Growth Rate | N/A |
| 5-Year Change | 248.39% |
| 10-Year Change | N/A |
| Growth Volatility | 22.03 |
Net Assets of Axonics Modulation Technologies Inc (2016–2023)
Net assets of Axonics Modulation Technologies Inc from 2016 to 2023. This chart illustrates how Axonics Modulation Technologies Inc's net assets have evolved over time, based on quarterly financial data. Also explore AXNX net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Net Assets for Axonics Modulation Technologies Inc (2016–2023)
The table below shows the annual net assets of Axonics Modulation Technologies Inc from 2016 to 2023. For live market cap and overall valuation, see Axonics Modulation Technologies Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $637.56 Million | +11.83% |
| 2022-12-31 | $570.14 Million | +18.18% |
| 2021-12-31 | $482.44 Million | +67.88% |
| 2020-12-31 | $287.37 Million | +57.03% |
| 2019-12-31 | $183.00 Million | +27.73% |
| 2018-12-31 | $143.28 Million | +505.26% |
| 2017-12-31 | $-35.35 Million | +2.55% |
| 2016-12-31 | $-36.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Axonics Modulation Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33124690800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Axonics Modulation Technologies Inc Net Assets Breakdown (December 2023)
Axonics Modulation Technologies Inc net assets breakdown by equity component as of December 2023.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $-15.87 Million | -2.49% |
| Other Components | $1.03 Billion | 162.14% |
| Total Equity | $637.56 Million | 100.00% |
Axonics Modulation Technologies Inc Competitors by Market Cap
The table below lists competitors of Axonics Modulation Technologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tevogen Bio Holdings Inc.
NASDAQ:TVGN
|
$40.89 Million |
|
JOSAPAR Joaquim Oliveira S.A. Participações
SA:JOPA3
|
$40.91 Million |
|
Tela Bio Inc
NASDAQ:TELA
|
$40.91 Million |
|
Honmyue Enterprise Co Ltd
TW:1474
|
$40.92 Million |
|
Triller Group Inc. Common Stock
NYSE:ILLR
|
$40.89 Million |
|
American Tungsten & Antimony Ltd
AU:AT4
|
$40.89 Million |
|
Fiyta Holdings Ltd
SHE:200026
|
$40.87 Million |
|
Petershill Partners PLC
LSE:PHLL
|
$40.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Axonics Modulation Technologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 570,139,000 to 637,564,000, a change of 67,425,000 (11.8%).
- Net loss of 6,088,000 reduced equity.
- Share repurchases of 15,447,000 reduced equity.
- Other comprehensive income increased equity by 9,280,000.
- Other factors increased equity by 79,680,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.09 Million | -0.95% |
| Share Repurchases | $15.45 Million | -2.42% |
| Other Comprehensive Income | $9.28 Million | +1.46% |
| Other Changes | $79.68 Million | +12.5% |
| Total Change | $- | 11.83% |
Book Value vs Market Value Analysis
This analysis compares Axonics Modulation Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.06x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-2.69 | $0.80 | x |
| 2017-12-31 | $-3.57 | $0.80 | x |
| 2018-12-31 | $20.47 | $0.80 | x |
| 2019-12-31 | $6.41 | $0.80 | x |
| 2020-12-31 | $7.77 | $0.80 | x |
| 2021-12-31 | $11.20 | $0.80 | x |
| 2022-12-31 | $12.21 | $0.80 | x |
| 2023-12-31 | $12.99 | $0.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Axonics Modulation Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.95%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1.66%
- • Asset Turnover: 0.51x
- • Equity Multiplier: 1.13x
- Recent ROE (-0.95%) is above the historical average (-14.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.46 Million |
| 2017 | 0.00% | -14097.05% | 0.00x | 0.00x | $-11.42 Million |
| 2018 | -22.67% | -4594.48% | 0.00x | 1.20x | $-46.81 Million |
| 2019 | -43.68% | -578.40% | 0.06x | 1.20x | $-98.24 Million |
| 2020 | -19.11% | -49.24% | 0.33x | 1.19x | $-83.65 Million |
| 2021 | -16.60% | -44.41% | 0.33x | 1.14x | $-128.31 Million |
| 2022 | -10.47% | -21.81% | 0.42x | 1.16x | $-116.71 Million |
| 2023 | -0.95% | -1.66% | 0.51x | 1.13x | $-69.84 Million |
Industry Comparison
This section compares Axonics Modulation Technologies Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,467,017,896
- Average return on equity (ROE) among peers: -49.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Axonics Modulation Technologies Inc (AXNX) | $664.49 Million | 0.00% | 0.17x | $40.89 Million |
| Abbott Laboratories (ABT) | $24.08 Billion | 18.37% | 0.83x | $179.28 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-132.02 Million | 0.00% | 0.00x | $2.72 Million |
| Aethlon Medical Inc (AEMD) | $-2.20 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $792.23 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.28 Million | -44.54% | 0.25x | $2.40 Million |
| Allurion Technologies, Inc. (ALUR) | $19.83K | -26.07% | 15.64x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $2.01 Million |
| Artivion Inc (AORT) | $300.73 Million | -4.93% | 1.64x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $63.86 Million | -18.63% | 0.16x | $105.31 Million |
About Axonics Modulation Technologies Inc
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retent… Read more